Form 13-F position report

IRONWOOD PHARMACEUTICALS INC

Reported by MORGAN STANLEY

IRWD CUSIP 46333X108 Manager CIK 0000895421

Reported 1,872,817 shares, up 12,903 (0.7%) from the prior quarter.

Reported value -5.0%; share count 0.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 1,872,817 Quarter-end amount reported
Reported value $7,435,084 Fair value at quarter end
Consecutive quarters held 54 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 12282000
2022-03-31 28731000
2022-06-30 29720000
2022-09-30 22827000
2022-12-31 32938902
2023-03-31 39965405
2023-06-30 32647126
2023-09-30 18304541
2023-12-31 24571038
2024-03-31 23326391
2024-06-30 31692602
2024-09-30 17804951
2024-12-31 17829389
2025-03-31 2738934
2025-06-30 354322
2025-09-30 625001
2025-12-31 2492739
2026-03-31 2895115
2026-06-30 7830240
2026-09-30 7435084

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for IRONWOOD PHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 1,872,817 +12,903 (0.7%) < 0.01% $7,435,084 2026-11-13
Q2 2026 Added 1,859,914 +1,035,095 (125.5%) < 0.01% $7,830,240 2026-08-13
Q1 2026 Added 824,819 +85,134 (11.5%) < 0.01% $2,895,115 2026-05-15
Q4 2025 Added 739,685 +262,585 (55.0%) < 0.01% $2,492,739 2026-02-13
Q3 2025 Reduced 477,100 -16,933 (-3.4%) < 0.01% $625,001 2025-11-14
Q2 2025 Reduced 494,033 -1,369,187 (-73.5%) < 0.01% $354,322 2025-08-15
Q1 2025 Reduced 1,863,220 -2,161,473 (-53.7%) < 0.01% $2,738,934 2025-05-15
Q4 2024 Reduced 4,024,693 -296,896 (-6.9%) < 0.01% $17,829,389 2025-02-14
Q3 2024 Reduced 4,321,589 -539,239 (-11.1%) < 0.01% $17,804,951 2024-11-14
Q2 2024 Added 4,860,828 +2,182,712 (81.5%) < 0.01% $31,692,602 2024-08-14
Q1 2024 Added 2,678,116 +530,298 (24.7%) < 0.01% $23,326,391 2024-05-15
Q4 2023 Added 2,147,818 +247,035 (13.0%) < 0.01% $24,571,038 2024-02-13
Q3 2023 Reduced 1,900,783 -1,167,556 (-38.1%) < 0.01% $18,304,541 2023-11-15
Q2 2023 Reduced 3,068,339 -730,654 (-19.2%) < 0.01% $32,647,126 2023-08-14
Q1 2023 Added 3,798,993 +1,140,486 (42.9%) < 0.01% $39,965,405 2023-05-15
Q4 2022 Added 2,658,507 +455,255 (20.7%) < 0.01% $32,938,902 2023-02-14
Q3 2022 Reduced 2,203,252 -374,222 (-14.5%) < 0.01% $22,827,000 2022-11-14
Q2 2022 Added 2,577,474 +293,650 (12.9%) < 0.01% $29,720,000 2022-08-15
Q1 2022 Added 2,283,824 +1,230,402 (116.8%) < 0.01% $28,731,000 2022-05-13
Q4 2021 Reduced 1,053,422 -654,367 (-38.3%) < 0.01% $12,282,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

237 managers reported IRONWOOD PHARMACEUTICALS INC for Q3 2026.

Managers reporting IRONWOOD PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 18,475,446 +686,889 < 0.01% $73,347,521 9 qtrs
ARMISTICE CAPITAL LLC Added 15,000,000 +1,068,000 0.73% $59,550,000 13 qtrs
Sarissa Capital Management LP Unchanged 9,188,635 0 23.82% $36,478,881 36 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 8,041,792 +48,566 0.04% $31,925,914 31 qtrs
STATE STREET CORPORATION Reduced 6,723,774 -2,085,827 < 0.01% $26,693,383 54 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 6,634,751 +26,243 < 0.01% $26,339,961 3 qtrs
Bank of America Corporation Reduced 5,218,957 -3,464,846 < 0.01% $20,719,260 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 5,063,802 -449,553 < 0.01% $20,103,294 3 qtrs
ACADIAN ASSET MANAGEMENT LLC Reduced 5,052,236 -801,095 0.02% $20,045,000 9 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 3,918,000 -913,657 < 0.01% $15,558,048 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
643,853
Shared
0
None
1,228,964

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.